BRPI0515118A - human growth hormone conjugates with polyethylene glycol - Google Patents
human growth hormone conjugates with polyethylene glycolInfo
- Publication number
- BRPI0515118A BRPI0515118A BRPI0515118-0A BRPI0515118A BRPI0515118A BR PI0515118 A BRPI0515118 A BR PI0515118A BR PI0515118 A BRPI0515118 A BR PI0515118A BR PI0515118 A BRPI0515118 A BR PI0515118A
- Authority
- BR
- Brazil
- Prior art keywords
- growth hormone
- human growth
- polyethylene glycol
- hgh
- hormone conjugates
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 7
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 7
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 7
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 230000006320 pegylation Effects 0.000 abstract 2
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CONJUGADOS DE HORMÈNIO DO CRESCIMENTO HUMANO COM POLIETILENO GLICOL. A presente invenção refere-se à PEGuilação do Hormónio do Crescimento humano (hGH) usando um PEG ramificado com glicerol. A presente invenção também refere-se a processos para a PEGuilação de hGH. Além disso, a presente invenção refere-se a composições farmacêuticas compreendendo o hGH PEGuilado. Uma modalidade adicional é o uso do hGH PEGuilado para o tratamento de distúrbios do crescimento ou do desenvolvimento.HUMAN GROWTH HORMONE CONJUGATES WITH POLYETHYLENE GLYCOL. The present invention relates to PEGylation of Human Growth Hormone (hGH) using a glycerol branched PEG. The present invention also relates to processes for the pegylation of hGH. Furthermore, the present invention relates to pharmaceutical compositions comprising pegylated hGH. An additional embodiment is the use of pegylated hGH for the treatment of growth or developmental disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
PCT/IB2005/002939 WO2006024953A2 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515118A true BRPI0515118A (en) | 2008-07-01 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515118-0A BRPI0515118A (en) | 2004-08-31 | 2005-08-25 | human growth hormone conjugates with polyethylene glycol |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (en) |
JP (1) | JP2008511610A (en) |
KR (1) | KR20070042567A (en) |
CN (1) | CN101010105A (en) |
AP (1) | AP2007003919A0 (en) |
AR (1) | AR050851A1 (en) |
AU (1) | AU2005278903A1 (en) |
BR (1) | BRPI0515118A (en) |
CA (1) | CA2577999A1 (en) |
CR (1) | CR8942A (en) |
EA (1) | EA200700380A1 (en) |
EC (1) | ECSP077281A (en) |
GT (1) | GT200500235A (en) |
IL (1) | IL181085A0 (en) |
MA (1) | MA28908B1 (en) |
MX (1) | MX2007002441A (en) |
NL (1) | NL1029828C2 (en) |
NO (1) | NO20071322L (en) |
PE (1) | PE20060654A1 (en) |
TN (1) | TNSN07078A1 (en) |
TW (1) | TW200621291A (en) |
UY (1) | UY29088A1 (en) |
WO (1) | WO2006024953A2 (en) |
ZA (1) | ZA200701802B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
IL144259A0 (en) | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US20090117077A1 (en) * | 2006-05-12 | 2009-05-07 | Dong-A Pharm. Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
JP2008069073A (en) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | Lactoferrin conjugate and its manufacturing method |
KR101079993B1 (en) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | Polyethylene glycol-G-CSF conjugate |
CL2008002399A1 (en) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
RU2483081C2 (en) * | 2008-07-23 | 2013-05-27 | Ханми Сайенс Ко.,Лтд.,Kr | Polypeptide complex containing non-peptidyl polymer, having three functional ends |
MX2011001167A (en) | 2008-07-31 | 2011-04-12 | Pharmaessentia Corp | Peptide-polymer conjugates. |
SG195531A1 (en) * | 2008-10-10 | 2013-12-30 | Bionic Ear Inst | Biodegradable polymer - bioactive moiety conjugates |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
SI2340271T1 (en) | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Polymer-bioactive agent conjugates |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
ES2610356T3 (en) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising the same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
CN101831067A (en) * | 2010-05-31 | 2010-09-15 | 王二新 | Polyethylene glycol ester conjugate and application thereof in medicine preparation |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (en) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof |
EP2947111B1 (en) * | 2013-01-17 | 2018-03-07 | Xiamen Sinopeg Biotech Co., Ltd. | Monofunctional branched polyethyleneglycol and bio-related substance modified by same |
CN104877127B (en) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification |
CA2964390A1 (en) | 2014-11-06 | 2016-05-12 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
ES2905105T3 (en) | 2017-12-29 | 2022-04-07 | Hoffmann La Roche | Procedure for Providing a PEGylated Protein Composition |
EP3731871B1 (en) * | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
SI3731873T1 (en) * | 2017-12-29 | 2022-05-31 | F. Hoffmann-La Roche Ag | Process for providing pegylated protein composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (en) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | Method for producing imidyl succinate-substituted polyoxyalkylene derivative |
CA2296770A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
JP3921781B2 (en) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | Carboxyl group-containing polyoxyalkylene compound |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
JP2005525302A (en) * | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | Chemically modified human growth hormone conjugates |
EP1546235B1 (en) * | 2002-09-09 | 2021-10-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
JP4412461B2 (en) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | Modified bio-related substance, production method thereof and intermediate |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
EP3593820A1 (en) * | 2003-05-23 | 2020-01-15 | Nektar Therapeutics | Peg derivatives containing two peg chains |
-
2005
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/en unknown
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/en active Pending
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/en not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/en unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/en unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/en active Pending
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/en not_active Application Discontinuation
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/en not_active Application Discontinuation
- 2005-08-29 UY UY29088A patent/UY29088A1/en not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/en unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/en not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/en unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/en unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/en not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/en unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/en unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/en unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/en unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NL1029828A1 (en) | 2006-03-01 |
PE20060654A1 (en) | 2006-08-12 |
EP1789092A2 (en) | 2007-05-30 |
TW200621291A (en) | 2006-07-01 |
MA28908B1 (en) | 2007-10-01 |
UY29088A1 (en) | 2006-03-31 |
WO2006024953A2 (en) | 2006-03-09 |
AP2007003919A0 (en) | 2007-02-28 |
MX2007002441A (en) | 2007-05-04 |
AR050851A1 (en) | 2006-11-29 |
ECSP077281A (en) | 2007-03-29 |
AU2005278903A1 (en) | 2006-03-09 |
CN101010105A (en) | 2007-08-01 |
IL181085A0 (en) | 2007-07-04 |
JP2008511610A (en) | 2008-04-17 |
WO2006024953A3 (en) | 2007-01-18 |
GT200500235A (en) | 2006-03-21 |
CA2577999A1 (en) | 2006-03-09 |
TNSN07078A1 (en) | 2008-06-02 |
KR20070042567A (en) | 2007-04-23 |
CR8942A (en) | 2007-08-16 |
NL1029828C2 (en) | 2006-10-20 |
NO20071322L (en) | 2007-05-29 |
ZA200701802B (en) | 2008-08-27 |
EA200700380A1 (en) | 2007-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515118A (en) | human growth hormone conjugates with polyethylene glycol | |
CY1118038T1 (en) | FOLLOWED PHARMACEUTICAL FORMS OF THERAPEUTIC DISPOSAL | |
CY1118731T1 (en) | ALVIGLUTIDIS PHARMACEUTICAL COMPOSITIONS | |
CL2009000349A1 (en) | Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease. | |
CY1113299T1 (en) | Protein Polypeptide for the Transfer of a Compound into the Blood-Cerebral Barrier | |
NI201000193A (en) | ORAL FORMULATIONS OF CITIDINE ANALOGUES AND METHODS OF USE OF THE SAME. | |
EA200802166A1 (en) | STABLE PHARMACEUTICAL COMPOSITION WITH PROTECTIVE ACTION AGAINST IRRITATION (OPTIONS), METHOD FOR ITS PREPARATION AND METHOD OF TREATING CALCIUM MIMETIC WITH IT WITH HELP | |
MY169272A (en) | Her2 antibody composition | |
BRPI0607762B8 (en) | glp-1 analogues, pharmaceutical composition containing them and use of a compound | |
MX2010007150A (en) | Recombinant vwf formulations. | |
BRPI0510526A (en) | stabilized liquid formulations of interferon | |
UY29004A1 (en) | SUBSTITUTED DERIVED COMPOUNDS OF ACIDS, GLYCIN AND ALANINE; PROCEDURE FOR PREPARATION AND USE. | |
BR0308429A (en) | Monocyclic Aroylpyridinones as Anti-Inflammatory Agents | |
EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
BR0214343A (en) | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 | |
BRPI0912411B8 (en) | use of a human interleukin-2 mutein (hil-2 mutein) and pharmaceutical composition for the treatment and/or prophylaxis of an autoimmune disease | |
CY1114803T1 (en) | Sulfonamide pyrimidine derivatives as chemokine receptor regulators | |
ECSP10010516A (en) | USE OF PEGILATED IGF-I VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
EA200970532A1 (en) | FUMARATE SALT (ALPHA S, BETA R) -6-BRUM-ALPHA- [2- (DIMETHYLAMINO) ETHYL] -2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-HINOLINETHANOL | |
CL2007000161A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER. | |
PA8803201A1 (en) | ACID DERIVATIVES OF CICLOALQUILAMINO | |
EA201370006A1 (en) | LOCAL PHARMACEUTICAL COMPOSITION CONTAINING FLURBIPROPHEN | |
NO330984B1 (en) | Amino acid phenoxy esters, processes for the preparation of such, intermediates in the synthetic route, pharmaceutical compositions comprising such and the use thereof for the preparation of pharmaceutical preparations for the treatment of disease | |
BR112012013164A2 (en) | pharmaceutical compositions for stem cell stimulation | |
BR0211761A (en) | depsipeptides and processes for preparing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/60 (2017.01) |